Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will join an expert panel of biotherapeutic leaders to discuss “Aligning Priorities with the Board” during the Longwood Healthcare Leaders Meeting. With experience as CEO of multiple pharmaceutical and biotechnology companies and as a member of various medical and business advisory boards, Dr. Fiore will provide unique insights into how executives and board members can work together to achieve company success.
“Understanding how company leaders and board members can support each other as they work toward common goals is a key to success,” said Dr. Fiore. “I look forward to sharing lessons I’ve learned throughout my career as both a CEO and a board member.”
The panel will take place at 1 pm ET on Thursday, May 5.
The Longwood Healthcare Leaders web conference will take place May 4-5, 2022 and focuses on topics affecting the biopharma ecosystem. Hosted by the Longwood Fund, an early-stage life science venture firm, the conference will bring together several hundred top biotech and pharmaceutical leaders.
About Exacis Biotherapeutics
Exacis is a development stage immuno-oncology company focused on harnessing the human immune system to cure cancer by engineering next generation off-the-shelf NK and T cell therapies aimed at hematologic malignancies and solid tumors. Exacis was founded in 2020 with an exclusive global license to a broad suite of patents covering the use of mRNA based cell reprogramming and gene editing technologies for use in generating engineered NK and T cells for oncology applications.
Exacis’ approach avoids the use of DNA and viruses and instead uses a proprietary mRNA based technology. Exacis uses the technology to generate iPSCs and to edit their genome to create stealthed, performance enhanced allogeneic NK and T cell products, termed ExaNK™, ExaCAR-NK™ and ExaCAR-T™ cells.
About T and Natural Killer (NK) Cell Therapies
T and NK cells are types of human immune cells that are able to recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.
Contact Exacis Biotherapeutics for further information and media: